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1. Introduction 
Methicillin resistant Staphylococcus aureus 
(MRSA) have been a concern in the recent 
years due to their emergence in livestock and 
the possible occupational hazards for humans 
in close contact with animals. In 2008, the 
European Commission (EC) took a decision of 
screening the population of pig farms in Europe 
for this new emerging pathogen, taking this 
screening into the framework of the baseline 
screening for Salmonella in pig farms 
(European Commission Decision 2008/55/EC). 
This screening has been performed in most 
European Countries by laboratories appointed 
by the national authorities and according to a 
common protocol defined by the EC. 
The European Union Reference Laboratory for 
Antimicrobial Resistance (EURL-AR) took part 
in the development and support of the 
laboratories by providing assistance in setting 
up the methods for isolation, identification, and 
typing of MRSA. Furthermore, the EURL-AR 
provided training in the specific methods on 
individual basis as well as in an MRSA training 
course that was organized in April 2009. 
In June 2009, the EURL-AR in addition to the 
External Quality Assurance System (EQAS) 
already performed, launched an MRSA specific 
EQAS, to enhance the capacity of the 
laboratories in MRSA isolation, identification 
and typing. This EQAS aimed at the 
identification of potential problems and 
identification of focus areas for 
training/education that might improve data 
quality in future European studies focusing on 
MRSA epidemiology. 
Initially, the first trials were aimed at isolation of 
MRSA from animal-related sources, such as 
dust isolates and swabs.  
The methods used in this EQAS reflect the 
methods recommended by EFSA technical 
specifications on the Scientific Report published 
by EFSA in 2012 on MRSA isolation, detection 
and typing methods (EFSA, 2012). 
In 2013, we launched the fifth EQAS performed 
on MRSA which included identification and 
typing of MRSA, and was based on pure 
isolates. Unlike the previous EQAS, the 
processing of isolates did not include isolation 
steps but identification of MRSA by molecular 
methods, species identification and detection of 
methicillin resistance (mecA and mecC gene) 
were mandatory items for confirmation of 
MRSA. An optional sequence based typing 
module based on spa typing was also offered. 
The spa typing trial was offered to increase 
capacity of laboratories in MS for performing 
standard MRSA typing using a method which is 
easily performed, and which results are robust 
and comparable to assess the epidemiology of 
MRSA in Europe.  
At this point, no mandatory surveillance for 
MRSA is defined by the European Commission. 
It is, however, considered relevant to enhance 
and/or maintain the objectives of this EQAS, i.e. 
the laboratories should have the methods 
implemented and ensure their performance. 
Therefore, this EQAS is aimed at preparing the 
laboratories for correctly performing the 
identification and molecular detection of MRSA 
and maintaining this capacity at MS level. 
No thresholds have been set in advance to 
evaluate the performance of the participating 
laboratories, or to classify the results of this 
EQAS.  
The MRSA EQAS was organized by the 
National Food Institute (DTU Food), Kgs. 
Lyngby, Denmark, and the 
verification/confirmation of the strains used in 
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the preparation of the test isolates was 
performed at the Food and Drug Administration 
Laboratory in the US (FDA). 
The data in this report are presented with 
laboratory codes. A laboratory code is known to 
the individual laboratory, whereas the entire list 
of laboratories and their codes is confidential 
and known only to the EURL-AR and the EU 
Commission. All conclusions are public. The 
technical advisory group for the EURL-AR 
EQAS scheme consists of competent 
representatives from all National Reference 
Laboratories for Antimicrobial Resistance 
(NRLs-AR), who meet annually at the EURL-AR 
workshop. 
 
2. Materials and Methods  
2.1 Participants in EQAS 2013 
A pre-notification (App 1), inviting the 
participants to the EQAS for antimicrobial 
susceptibility testing of Staphylococci, 
Enterococci and E. coli and for the MRSA 
EQAS 2013 was issued by e-mail to the EURL-
AR network on the 15th of April 2013 to the 
NRL-AR’s. Additionally, the laboratories that 
participated in the MRSA baseline studies in 
2008 and participated in the MRSA EQAS in the 
previous year were invited to participate using 
the same pre-notification. 
All participants were included in a participant list 
(App 2) before the preparation and shipping of 
the isolates. Participation was free of charge 
but each laboratory was expected to cover 
expenses associated with their own analysis.  
2.2 Preparation of isolates for 
shipment 
Ten stab cultures containing Staphylococcus 
spp were prepared for identification of species, 
detection of methicillin resistance, and typing. 
The isolates were either methicillin-resistant 
Staphylococcus aureus (MRSA), methicillin-
susceptible S. aureus (MSSA), methicillin 
resistant or susceptible S. pseudintermedius 
(MRSP or MSSP) and/or coagulase negative 
staphylococci strains (CNS). Eight of the test 
isolates selected for the MRSA EQAS were the 
same isolates as those to be used in the EQAS 
for antimicrobial susceptibility testing of S. 
aureus and two were additionally prepared for 
this EQAS, exclusively (EURL-ST 7.9 and ST 
7.10). The isolates were prepared in advance 
and subcultured in weeks 21-23 before agar 
stick preparation. Homogeneity tests were 
performed for ensuring the purity of the agar 
stick cultures, and MRSA identification and 
antimicrobial susceptibility profiles were 
confirmed.  
The strains used for the EQAS were selected 
from the strain collections at DTU-Food and the 
identifications were confirmed by PCR and 16S 
rDNA and/or spa detection and sequencing. 
Furthermore, the spa types of the MRSA 
isolates were determined by PCR and 
sequencing and assigned according to the spa 
server using Bionumerics (App 3). Identification 
and the spa type of the selected isolates were 
verified and confirmed by parallel analysis 
conducted at FDA in the US. 2.3 Identification 
of MRSA  
The protocol for identification of the MRSA 
isolates was made available on the EURL-AR 
website (http://www.eurl-ar.eu) (App.4). The 
protocol for identification of methicillin 
resistance recommended was the same as in 
2012 based on a multiplex PCR able to detect 
both mecA and mecC genes and to 
simultaneously amplify fragments of the spa 
and pvl genes (Stegger et al., 2012).  
2.4 spa typing 
The isolates used for this EQAS were typed by 
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a single locus sequence typing method - spa 
typing (Shopsin et al. 1999) and in addition the 
spa-types were verified at the FDA. 
The laboratories with capacity to perform spa 
typing were invited to submit the spa typing 
results to the MRSA EQAS database, which 
were evaluated for accuracy against the 
expected spa types. 
2.5 Distribution 
The agar sticks containing stab cultures were 
kept at 4°C between the preparation and 
shipment process (2-4 weeks). The tubes 
containing the cultures in nutrient agar were 
enclosed in double pack containers (class UN 
6,2) and sent to the selected laboratories 
according to the International Air Transport 
Association (IATA) regulations as “Biological 
Substance category B” classified UN3373. The 
parcels were dispatched from DTU-Food on 
June 17th, 2013.  
2.6 Procedure 
The laboratories were instructed to download 
the protocol and test forms (App. 4 and 5), from 
http://www.eurl-ar.eu 
The EQAS protocol was based on the method 
recommended by the EURL-AR for the 
identification of the MRSA isolates using a 
multiplex PCR which would allow identification 
of S. aureus and also identify the mecA and 
mecC genes, mandatory for the classification of 
isolates as MRSA, Regarding spa typing the 
standard recommended spa typing procedure 
was recommended (App 4). 
After completion of the tests, the laboratories 
were requested to enter the obtained results 
into an electronic record sheet in the EURL-AR 
web based database through a secured 
individual login, or alternatively send the record 
sheets by fax to DTU Food (App 5). The 
database was activated on the June 21st, 2013 
and closed after the deadline on September 
10th, 2013 and the evaluation reports were 
made available by this date. 
The isolates were categorised as positive or 
negative in function of the identification of 
MRSA isolates. Negative isolates could be 
subdivided into different categories (negative 
isolate, MSSA, MRCNS, MRSP, CNS), 
however, they would be grouped as negative. 
Final interpretations of the results obtained 
were compared to the expected results and 
classified as correct or incorrect without further 
classification of the deviation.  
As an optional item, results of spa types were 
requested for typing the positive MRSA isolates. 
In this case, the participants would be invited to 
choose the obtained spa type from a pick list, 
and the typing result would be evaluated 
against the expected spa type and classified 
into correct or incorrect.  
3. Results 
A total of 34 laboratories; including 26 NRLs, six 
additional non-NRLs in EU and laboratories 
from Norway and Switzerland responded to the 
pre-notification, and were enrolled in the EQAS.  
When the deadline for submitting results was 
reached, 32 laboratories in 26 European 
countries (including Switzerland and Norway) 
had uploaded data. Two of the laboratories 
decided not to take part due to technical issues 
(Lab #39 and #40). 
One laboratory or more from each of the 
following countries provided results to the 
EQAS (Figure 1): Austria, Belgium, Croatia, 
Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Hungary, Ireland, 
Italy, Latvia, Lithuania, the Netherlands, 
Norway, Poland, Portugal, Romania, Slovakia, 
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Slovenia, Spain, Sweden, Switzerland, and UK.  
 
Figure 1. Participating countries in MRSA EQAS 2013. Participating countries are marked in green for laboratories 
participating in MRSA identification.Dark blue represents countries participating in the spa typing as well 
 
 
 
3.1 Methods used by EQAS-
participants 
Of the 32 laboratories submitting results, all 
(100%) of the laboratories participated in the 
MRSA identification module whereas only 17 
laboratories (53%) participated in the optional 
spa typing module offered. 
Information on the methods used for isolation, 
identification and typing was collected from the 
participants through the database.  
The confirmatory testing of S. aureus was 
performed using the current EURL-AR 
recommended PCR-protocol containing the 
mecA, mecC, pvl and spa gene in most 
laboratories uploading results (n=21) and the 
other referred methods for identification 
included the former EURL-AR-recommended 
method (n=3), other published (n=2) or in-
house PCR and RT-PCR methods (n=2). The 
remaining laboratories did not reply to this 
question. 
The species identification was mostly 
performed by PCR, using the EURL-AR 
recommended PCR primers (n=14), however, 
six laboratories used the former protocol for this 
purpose. Other methods included using other 
published or in-house PCR methods in the 
remaining laboratories that reported methods 
(n=3). As additional identification methods, 
some participating laboratories added nuc and 
femB PCR, coagulase tests, biochemical tests, 
Vitek and MALDI-TOF identification systems to 
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confirm the species ID for some or all of the test strains.
 
Table 1. The overall performance of MRSA identification, 2013. 
 
Identification of MRSA isolates Correctly classified isolates 
Number of performed tests Number of correct tests N(%) 
n % N % 
314 100 308 98% 
Number of expected negative tests Number of correctly identified negative tests 
n % N % 
122 40% 119 98% 
Number of expected positive tests Number of correctly identified positive tests 
n % N % 
192 60% 189 98% 
 
 
3.2 MRSA identification 
A total of 314 tests, were performed and the 
overall result indicate that 308 tests were 
correct, corresponding to 98%. From the 122 
tests performed on the four strains expected to 
be negative, 98% (n=119) were correctly 
assigned, and the remaining three were found 
false positive. Regarding the 192 tests 
performed on the six strains expected to be 
found positive, also 98% of these were correctly 
found positive (n=189) (Table 1). 
The results per strain show that deviations were 
observed for strains ST 7.1, 7.4, 7.6, 7.8, 7.9 
and 7.10 and accounting one deviation for each 
strain.  
An internal control was prepared in order to 
have one strain in common to former MRSA 
EQAS trials (2009, 2010 and 2012). The 
internal control was isolate EURL-ST 7.4 
(MRSA, spa t075).  
The individual laboratory results provided data 
for all strains (except for Lab #12 that provided 
results for seven strains and Lab #30, #31 and 
#35 that provided results for nine of the strains, 
leaving out ST 7.10) In general, the test results 
of this MRSA EQAS showed a very good 
sensitivity and specificity by most laboratories, 
indicated by the general accuracy of the tests at 
98%. Overall, only three false negatives and 
three false positives were observed.  
The five laboratories obtaining deviations had 
one or two deviations among the ten isolates 
shipped (Graph 1). 
The laboratory showing the largest number of 
deviations (Lab #6) failed to identify the MRSA 
carrying the mecC gene (ST 7.1) and 
considered strain ST 7.10 (S. 
pseudintermedius) to be MRSA. These 
mistakes (20% deviation) might be explained by 
the method used for identification and 
confirmation of MRSA (the former PCR method) 
which did not detect the mecC gene or the spa 
gene. Detection of these genes would 
distinguish strain ST 7.10 from S. aureus 
species. Furthermore, this laboratory is not 
performing any surveillance at the MS level for 
MRSA, and did not previously participate in this 
EQAS. 
Regarding the remaining laboratories that 
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obtained deviations, they all had one deviation 
each. In the case of lab #30 the laboratory had 
11% deviations (one out of nine results 
uploaded) and the deviation observed was 
caused by a false positive result for strain ST 
7.6 which was an expected MSSA. The 
deviations found by lab #19 and #51 were false 
negative results caused by misidentification of 
ST 7.4 and ST 7.8 which were both MRSA, 
identified as CNS. Finally, the deviation 
obtained by lab #58 was due to the 
misidentification of ST 7.9 as MRSA where 
CNS was expected. 
 
 
 
 
Graph 1: Number of deviations per laboratory for identification of methicillin resistant S. aureus (MRSA) 
 
3.3 spa typing of the MRSA strains 
In the spa typing module, 17 laboratories 
participated by uploading spa typing data.  
The reported results for spa typing included 99 
tests and the general results show that 98 
(99%) of the results were considered correct, 
whereas one (1%) deviation was observed.  
In this module, isolates ST 7.1, ST 7.3, ST 7.4, 
ST 7.5, ST7.7 and ST 7.8 were expected to be 
identified positive for MRSA whereas the 
remaining negative strains ST 7.2, ST 7.6, ST 
7.9 and ST 7.10 were either MSSA or non-S. 
aureus and were therefore not expected to be 
spa typed (Table 2).  
In this way, the range of uploaded spa types 
diverged from one to ten strains uploaded by 
each participating laboratory but only the spa 
typing results corresponding to the six expected 
MRSA strains were evaluated.  
Sixteen laboratories had no deviations, and 
only one laboratory had one deviation (lab #1) 
due to incorrect spa type assignment; t127 was 
reported, whereas t075 was expected.  
Additionally, eleven laboratories uploaded 
results of spa typing for MSSA strains ST 7.2 
and ST 7.6, in a total of 22 tests which, if 
evaluated, were correct spa types (n=19). This 
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indicates that the protocol was probably unclear 
and could be misunderstood by the participants. 
One laboratory (Lab #30) uploaded an incorrect 
spa type for MSSA strain ST 7.6 (t2582), which 
was probably due to a switch in strains with ST 
7.5 as the same laboratory incorrectly identified 
this strain as MRSA.  
For the non-S. aureus strains, ST 7.9 and 7.10, 
11 and 8 laboratories, respectively, submitted 
the result “not applicable” 
 
 
Table 2. Results of the spa typing trial per isolate. 
Isolate 
number 
N 
participating 
laboratories 
Repeat succession expected spa type correct 
Deviating 
results 
(number 
of 
deviations
) 
EURL-ST 7.1 17 04-82-17-25-17-25-25-16-17 t843 17 None 
EURL-ST 7.2 12 N/A N/A (t127) N Ev  - 
EURL-ST 7.3 17 08-16-02-25-02-25 t1250 17 None 
EURL-ST 7.4 17 11-19-21-21-12-21-17-34-24-34-22-25 t075 16 t127 (1) 
EURL-ST 7.5 16 08-16-02-25-02-25-02-25-34-24-25 t2582 16 None 
EURL-ST 7.6 10 N/A N/A (t3855) N Ev  - 
EURL-ST 7.7 16 08-34-24-25 t4571 16 None 
EURL-ST 7.8 16 08-16-02-25-24-25 t108 16 None 
EURL-ST 7.9 8 N/A N/A N Ev  - 
EURL-ST 7.10 11 N/A N/A N Ev  - 
     
     N/A- not applicable 
     N Ev- not evaluated 
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4. Discussion
4.1 MRSA identification 
In the 2013 EURL-AR MRSA EQAS trial, the 
strains were sent as agar stab cultures for the 
first time, and therefore the isolation part of the 
trial performed in the former years was not 
included.  
The results were overall very good and both 
expected MRSA and non-MRSA were mostly 
well classified, with few exceptions of three 
false negative and three false positive results, 
leading to 98% accuracy, overall. One of the 
laboratories showed 20% deviation. This might 
be explained by the use of a method differing 
from the recommended for the MRSA 
identification and mecA/mecC detection. 
Additionally, two laboratories that registered, 
still had technical issues and were not able to 
set up the methods for this trial in time and 
therefore did not upload any data. 
It is recommended to use the EURL-AR 
recommended PCR method to improve the 
results, to be able to correctly identify the S. 
aureus strains and detect both mec-gene 
variants. Further laboratories showing 
deviations had issues with species identification 
and should therefore look deeper into their 
methods and use the recommended EURL-AR 
method as well as check the management and 
QC in the laboratory to avoid possible switches 
or contaminations of test strains. 
4.2 spa typing 
For spa typing, 17 laboratories participated in 
the trial which indicates a good level of 
participation even though no MRSA monitoring 
is ongoing in the EU. The results uploaded were 
excellent, with sixteen of the 17 laboratories 
showing no deviation. The deviating spa-type 
result was most likely caused by handling of the 
test strain as the obtained spa type could be 
from another EQAS test strain (MSSA). 
Results from MSSA and non-S. aureus were 
not required to be spa typed by the protocol, 
however this might have not been very clearly 
stated  as many laboratories have uploaded 
spa types for the MSSA strains instead of 
selecting the “non applicable” option. This is 
rather controversial as it is possible to spa type 
MSSA strains and the results would have been 
very good in general if that was the case, 
however, as was mentioned in the protocol that 
this was not intended, these results were not 
taken up in the evaluation.  This can be 
explained by the fact that, in case of MRSA 
monitoring, the laboratories would not be 
required to provide spa types for the detected 
MSSA, but only the MRSA. To avoid unfair 
deviations resulting from uploading spa types 
instead of the “non applicable” option, none of 
the results uploaded for these strains were 
evaluated in this trial. 
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5. Conclusion 
In general, the results of the fifth MRSA EQAS 
2013 demonstrate that most participating 
laboratories have set up the relevant methods 
and are able to identify MRSA in a reliable 
fashion using molecular methods. As there is 
currently no MRSA monitoring in the EU, it is 
not the NRL’s first priority to have this method 
running, however, given the importance of 
MRSA, the EURL-AR will strive towards having 
the remaining laboratories setting up the MRSA 
identification and confirmation at the MS level. 
The frequency of the MRSA EQAS will be 
reduced to every second year to keep 
preparedness at country level for MRSA 
detection and identification. 
The participation in the spa typing module 
indicates that 53% of the laboratories have this 
method available. However, still fifteen 
laboratories participating in the MRSA EQAS 
2013 did not take part in the optional spa typing 
module. This might indicate that these 
laboratories have prioritized spa typing lower or 
did not set up this methodology.  
The results of the spa-typing module show that 
spa typing as expected is a reproducible 
method which did not cause major problems 
relative to the execution or interpretation in the 
participating laboratories. Only one deviation 
was observed in this module due to incorrect 
spa type assignment which might be due to 
switching or cross contamination between two 
EQAS strains, which again shows the need of 
controlling the analysis process in every step, to 
obtain a reliable final result. 
 
6. References
European Commission, 2008. COMMISSION 
DECISION of 20 December 2007 concerning a 
financial contribution from the Community 
towards a survey on the prevalence of 
Salmonella spp. and Methicillin-resistant 
Staphylococcus aureus in herds of breeding 
pigs to be carried out in the Member States. 
Decision 2008/55/EC in: 
http://ec.europa.eu/food/food/biosafety/salmone
lla/impl_reg_en.htm 
 
EFSA 2012. Scientific report on technical 
specifications on the harmonised monitoring 
and reporting of antimicrobial resistance in 
methicillin-resistant Staphylococcus aureus 
EFSA Journal;10(10):2897.  
Shopsin B, Gomez M, Montgomery SO, Smith 
DH, Waddington M, Dodge DE, Bost DA, 
Riehman M, Naidich S, Kreiswirth BN. 
Evaluation of protein A gene polymorphic region 
DNA sequencing for typing of Staphylococcus 
aureus strains. J Clin Microbiol. 1999 
Nov;37(11):3556-63. 
Stegger M, Andersen PS, Kearns A, Pichon B, 
Holmes MA, Edwards G, Laurent F, Teale C, 
Skov R, Larsen AR. Rapid detection, 
differentiation and typing of methicillin-resistant 
Staphylococcus aureus harbouring either mecA 
or the new mecA homologue mecA(LGA251). 
Clin Microbiol Infect. 2012 Apr;18(4):395-400. 
 
12 
 
Page 1 of 1 
                                                                      
M00-06-001/01.12.2011  
________________________________________________________________________________________________ 
EU Community Reference Laboratory, Antimicrobial Resistance, Kemitorvet, Building 204, DK-2800 Kgs. Lyngby, Denmark 
Ph: + 45 3588 6269, Fax: + 45 3588 6341, e-mail: licav@food.dtu.dk 
 
Appendix 1- EURL-AR EQAS pre-notification 
EQAS 2013 FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING OF E. COLI, 
STAPHYLOCOCCI AND ENTEROCOCCI, AND IDENTIFICATION AND TYPING OF MRSA 
 The EURL-AR announces the launch of another EQAS, thus providing the opportunity for proficiency 
testing which is considered an essential tool for the generation of reliable laboratory results of consistently 
good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight E. coli isolates, eight staphylococci and 
eight enterococci isolates. The EQAS on identification and typing of MRSA strains will consist on the 
confirmation of identification and methicillin resistance by multiplex PCR for the eight Staphylococcus 
isolates and two isolates provided additionally for the MRSA trial. Additionally, spa typing of the strains 
confirmed as MRSA is offered as an optional module. 
Additionally, quality control (QC) strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 
4224), S. aureus ATCC 25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) 
(for MIC) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance and additional designated laboratories 
performing the selective isolation and identification of MRSA from pig farms. These laboratories do not 
need to sign up to participate but are automatically regarded as participants. You may contact the EQAS-
coordinator, if you wish to inform of changes. Participation is free of charge for all above-mentioned 
designated laboratories. 
 TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: eight E. coli, ten staphylococci, 
eight enterococci and for new participants also the QC strains mentioned above. Please provide the EQAS 
coordinator with documents or other information that can simplify customs procedures (e.g. specific text that 
should be written on the pro-forma invoice). To avoid delays, we kindly ask you to send this information 
already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in June 2013. The protocol for this 
proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than the 6th of 
September 2013 via the password-protected website. Upon reaching the deadline, each participating 
laboratory is kindly asked to enter the password-protected website once again to download an automatically 
generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In the report, 
laboratories will be presented coded, which ensures full anonymity. The EURL-AR and the EU Commission, 
only, will have access to un-coded results. The report will be publicly available. 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing of 
Salmonella and Campylobacter which will be carried out in October 2013 
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
 
Lina Cavaco - EURL-AR 
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Appendix 2- Participant List 
 
Registered 
MRSA 
ID spa Institute   Country 
x x x Austrian Agency for Health and Food Safety  Austria 
x x x Veterinary and Agrochemical Research Centre Belgium 
x     Nacional Diagnostic and Research Veterinary Institute Bulgaria 
x x   Croatian Veterinary Institut Croatia 
x x   Veterinary Services  Cyprus 
x x   SVI Olomouc 
Czech 
Republic 
x x x National Food Institute Denmark 
x x   Estonian Veterinary and Food Laboratory Estonia 
x x x Finnish Food Safety Authority EVIRA Finland 
x x x 
Agence nationale de sécurité sanitaire ANSES - Ploufragan and 
Maisons-Alfort France 
x x x Federal Institute for Risk Assessment  Germany 
x x   Veterinary Laboratory of Chalkis Greece 
x x x Central Agricultural Office Veterinary Diagnostic Directorate Hungary 
x x   Central Veterinary Research Laboratory Ireland 
x x x 
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e 
Toscana Italy 
x x x Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia 
x x   National Food and Veterinary Risk Assessment Institute Lithuania 
x     Public Health Laboratory Malta 
x x   Food and Consumer Product Safety Authority (VWA) Netherlands 
x x   Central Veterinary Institute of Wageningen UR Netherlands 
x x x Veterinærinstituttet Norway 
x x   National Veterinary Research Institute Poland 
x x   Laboratorio National de Investigacáo Veterinaria  Portugal 
x x x Faculdade de Medicina Veterinária UTL Portugal 
x x   Institute for Hygiene and Veterinary Public Health Romania 
x x   Institute for Diagnosis and Animal Health Romania 
x x   State Veterinary and Food Institute  (SVFI) Slovakia  
x x x National Veterinary Institute Slovenia 
x x   Laboratorio Central de Sanidad, Animal de Santa Fe  Spain 
x x x VISAVET Health Surveillance Center, Complutense University Spain 
x x x National Veterinary Institute, SVA Sweden 
x x x Vetsuisse faculty Bern, Institute of veterinary bacteriology Switzerland 
x x x Faculty of Veterinary Medicine, 
The 
Netherlands 
x x x The Veterinary Laboratory Agency 
United 
Kingdom 
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Appendix 3- Expected results 
 
 
CODE species spa  mecA mecC status MRSA conclusion 
 Spa 
MSSA 
EURL ST 7.1 S. aureus t843 neg pos MRSA Positive   
EURL ST 7.2 S. aureus 
Not 
applicable neg neg MSSA Negative  (t127) 
EURL ST 7.3 S. aureus t1250 pos neg MRSA Positive   
EURL ST 7.4 S. aureus t075 pos neg MRSA Positive   
EURL ST 7.5 S. aureus t2582 pos neg MRSA Positive   
EURL ST 7.6 S. aureus 
Not 
applicable neg neg MSSA Negative (t3855) 
EURL ST 7.7 S. aureus t4571 pos neg MRSA Positive   
EURL ST 7.8 S. aureus t108 pos neg MRSA Positive   
EURL ST 7.9 S. haemolyticus 
Not 
applicable neg neg CNS Negative   
EURL ST 7.10 S. pseudintermedius 
Not 
applicable pos neg MRSP Negative   
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Appendix 4- PROTOCOL  
For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci, 
and identification and typing of MRSA 
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3. OUTLINE OF THE EC/ENT/STAPH EQAS 2013    ............................................................. 2
3.1 Shipping, receipt and storage of strains    ..................................................................... 2
3.2 Suggested procedure for reconstitution of the lyophilised reference strains    ......... 2
3.3 Antimicrobial susceptibility testing    ............................................................................ 3
4. REPORTING OF RESULTS AND EVALUATION    ........................................................... 7
4.1 AST of E. coli, enterococci and staphylococci    ........................................................... 7
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5. HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE    ............................. 8
5.1 AST of E. coli, enterococci and staphylococci    ........................................................... 8
5.2 EQAS on identification and typing of MRSA    ........................................................... 9
 
1. INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci, and 
identification and typing of MRSA is among the tasks of the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph EQAS 2013 will include AST of eight E. 
coli, eight enterococci and eight staphylococci strains and AST of reference strains E. coli ATCC 
25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), S. aureus ATCC 25923 (CCM 3953) 
(for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) (for MIC). The above-mentioned 
reference strains are included in the parcel only for new participants of the EQAS who did not 
receive them previously. The reference strains are original CERTIFIED cultures provided free of 
charge, and should be used for future internal quality control for antimicrobial susceptibility testing 
in your laboratory. The reference strains will not be included in the years to come. Therefore, please 
take proper care of these strains. Handle and maintain them as suggested in the manual ‘Subculture 
and Maintenance of QC Strains’ available on the EURL-AR website (see www.eurl-ar.eu).  
Page 2 of 10 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2013 
 
 
 
 
M00-06-001/21.06.2013 
The strains included in the identification and typing of MRSA are the eight staphylococci strains for 
AST together with two additional Staphylococcus strains. This component of the EQAS functions 
as a continuation of the previous MRSA EQAS to evaluate the proficiency of the laboratories on 
procedures for confirmatory testing and spa typing.  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
1. OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
to EFSA by different laboratories, and to harmonise the breakpoints for antimicrobial susceptibility 
used within the EU. Additionally, with the MRSA confirmation and spa typing components 
included in this iteration, we intend to continue the harmonization and /or implementation process 
of MRSA monitoring at the NRL level. 
2. OUTLINE OF THE EC/ENT/STAPH EQAS 2013 
2.1. Shipping, receipt and storage of strains 
In June 2013, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight E. coli, eight enterococci and ten staphylococci strains from the 
National Food Institute, Denmark (two of the staphylococci strains are to be included in the MRSA 
components, only). This parcel will also contain reference strains, but only for participants who did 
not receive them previously. All strains belong to UN3373, Biological substance, category B. 
Extended spectrum beta-lactamase (ESBL)-producing strains as well as methicillin resistant 
Staphylococcus aureus (MRSA) will be included in the selected material.  
The reference strains are shipped lyophilised, while the test strains are stab cultures. On arrival, the 
stab cultures must be subcultured, and all cultures should be kept refrigerated until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below.  
2.2. Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported on 
the EURL-AR-website (see www.eurl-ar.eu). 
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2.3. Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below.
Participants performing minimum inhibitory concentration (MIC) determination should use the 
values listed in Tables 1, 2 and 3 for interpretation of results. These values represent the 
epidemiological cut-off values developed by EUCAST (
  
www.eucast.org), and allow categorisation 
of bacterial isolates into two categories: Resistant or susceptible. A categorisation as intermediate is 
not accepted, and intermediate results should be interpreted as susceptible.  
Participants using disk diffusion are recommended to interpret the results according to the 
breakpoints used routinely. However, when testing E. coli by disk diffusion, the interpretation of 
ciprofloxacin results should be done according to the guidelines described by Cavaco and Aarestrup 
in J Clin Microbiol. 2009 Sep;47(9):2751-8. Strains must be categorised resistant and susceptible. 
Also in this case, a categorization as intermediate is not accepted, and intermediate results should 
be interpreted as susceptible. 
 
E. coli  
Table 1: Antimicrobials recommended for AST of Escherichia coli and interpretative criteria 
Antimicrobials for E. coli MIC (µg/mL) R is > 
Ampicillin, AMP 8 
Cefepime 0.125 
Cefotaxime, CTX 0.25  
Cefoxitin, FOX 8 
Ceftazidime, CAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.06  
Colistin 2 
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Meropenem, MER 0.125 
Nalidixic acid, NAL 16 
Sulfonamides, SMX 64 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
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Plasmid-mediated quinolone resistance 
When performing antimicrobial susceptibility testing of E. coli, the interpretative criteria listed in 
Table 1 for results obtained by MIC-determination detect plasmid mediated quinolone resistant test 
strains. When interpreting a disk diffusion result, reference should be made to the guidelines in 
described by Cavaco and Aarestrup in J Clin Microbiol. 2009 Sep;47(9):2751-8. 
Beta-lactam resistance 
Confirmatory tests for ESBL production are mandatory on all strains resistant to cefotaxime 
(CTX), ceftazidime (CAZ) or meropenem. 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; 
MIC CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for 
either antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone 
(CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Resistance to cefepime gives further indication of ESBL production. 
Confirmatory test for carbapenemase production requires the testing of meropenem (MER).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that may be verified by PCR and sequencing. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 2012), indicating as: 
• Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and resistant 
to cefepime 
• Presumptive ESBL+pAmpC: -strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime 
• Presumptive pAmpC phenotype: -strains with negative synergy test  
• Presumptive carbapenemase phenotype: -strain resistant to meropenem 
• Unusual phenotype: any other combinations 
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The EURL-AR aims to harmonise with the new EU monitoring and the EUCAST expert rules. 
Accordingly, MIC values and relative interpretation of cefotaxime, ceftazidime and meropenem 
used for detection of beta-lactamase-producing strains in this EQAS should be reported as found.  
 
Enterococci  
Table 2: Antimicrobials recommended for AST of Enterococcus spp. and interpretative criteria 
 
Antimicrobials for enterococci MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Daptomycin, DAP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Quinupristin-dalfopristin (Synercid), SYN 4* Not applicable 
Teicoplanin 2 2 
Tetracycline, TET 4 4 
Tigecycline, TGC 0,25 Not applicable 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org)  
 
Identification of the Enterococcus spp. 
In 2013, species identification of the Enterococci must be performed by the NRLs using in-house 
methods or adopting the protocol available on the EURL-AR website under: http://eurl-ar.eu/233-
protocols.htm.  
 
Staphylococci  
Eight of the staphylococci strains sent should be tested both in the AST component and in the 
MRSA components (EURL ST-7.1 to ST-7.8) whereas the two additional strains (EURL ST-7.9 
and 7.10) are intended for the MRSA EQAS components only. 
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Table 3: Antimicrobials recommended for AST of Staphylococcus aureus and interpretative criteria 
Antimicrobials for S. aureus MIC (µg/mL) R is > 
Cefoxitin, FOX 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Clindamycin, CLI 0.25 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 2 
Linezolid, LNZ 4 
Mupirocin, MUP 1 
Penicillin, PEN 0.125* 
Quinupristin-dalfopristin (Synercid), SYN 1 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 2 
Vancomycin 2 
*CLSI M100 Table 2C 
 
Identification and typing of MRSA 
All ten staphylococci (ST 7.1 to 7.10) are to be used in the MRSA identification and typing 
components of the proficiency test. Some test strains may be methicillin-resistant. Confirmation of 
mecA and/or mecC presence is mandatory in this EQAS. For this purpose, you are welcome to 
use the method you prefer, and upload the result as ‘positive’ or ‘negative’. According to CLSI 
recommendations (M100, Table 2C), all MRSA should be regarded as resistant to all β-lactam 
antibiotics. 
The ten staphylococci strains are either positive or negative for methicillin resistance and or, 
represent other methicillin susceptible or resistant Staphylococcus species. 
 
As part of the identification and typing of MRSA, handle the strains as follows:   
 
1. Take up the strains from the agar sticks and plate onto a blood agar plate (you may use 
additional selective media, but it is not compulsory).  
2. Incubate 24-48 h at 37 °C.  
3. Observe the colony morphology of the isolates on the blood agar plate (colour, appearance, 
haemolysis). Check for purity.  
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4. At this stage, the isolates should either be processed immediately or stored under appropriate 
conditions (–80°C) for later identification and characterisation. 
 
Identification of MRSA 
Presumptive MRSA isolates should be confirmed as Staphylococcus aureus isolates carrying the 
mecA gene or the mecC gene (previously known by mecALGA251) by PCR. There is no need to 
perform other screening methods (such as screening with either oxacillin or cefoxitin), thus, the 
presence of the mecA or mecC gene can be directly confirmed by PCR amplification. The species 
identification is simultaneously confirmed by using the EURL-AR recommended multiplex PCR 
protocol (http://eurl-ar.eu/233-protocols.htm) including the amplification of the spa gene (specific for 
Staphylococcus aureus species and may be sequenced for spa typing), the mecA-gene and the mecC 
gene (both encoding methicillin resistance) and the pvl gene (encoding the Panton Valentine 
Leukocidin).  
 
Spa typing  
Spa typing of the MRSA isolates may be performed additionally if the laboratory has the capacity to 
perform and analyse the spa-typing data. In case you decide to include spa types in the submitted 
data, these will be evaluated on the accuracy of the spa typing. 
 
 
3. REPORTING OF RESULTS AND EVALUATION 
3.1. AST of E. coli, enterococci and staphylococci 
 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range and/or antimicrobial 
disk content. Finally, if you did not use the cut-off values recommended in the protocol for 
interpretation of AST results, please report the breakpoints used in the database. 
3.2. MRSA identification and typing 
Fill in your results in the enclosed MRSA EQAS test forms. Please enter your results into the 
interactive web database. Please read the detailed description below before entering the web 
database. When you enter the results via the web, you will be guided through all steps on the screen 
and you will immediately be able to view and print a submission report of your results.  
3.3. General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than September, 6th 2013. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
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once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please return the completed test forms by e-
mail, fax or mail to the National Food Institute, Denmark.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact us: 
Lina Cavaco 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204 st room 51,  
DK-2800 Kgs. Lyngby 
Denmark 
Tel: +45 3588 6269 
Fax: +45 3588 6341 
E-mail: licav@food.dtu.dk 
 
4. HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2013 start web page (http://thor.dfvf.dk/crl), write your username and 
password in lower-cases and press enter. Your username and password are the same used in the 
previous EQAS’s arranged by The National Food Institute, Denmark. Do not hesitate to contact us 
if you experience problems with the login. 
You can browse back and forth by using the back and forward keys and by clicking on the EURL 
logo. 
4.1. AST of E. coli, enterococci and staphylococci 
Click on either “E. coli test results”, “enterococci test results” or “staphylococci test results” based 
on the results you are going to upload. The description reported below is based on Salmonella test 
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result entry, but it is the exact same procedure for entering E. coli, enterococci and staphylococci 
test results. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing of Salmonella 
and the brand of discs, tablets, MIC trays, etc.  
Fill in the fields related to either antimicrobial disk content or tested MIC range. If you used disk 
diffusion, please upload the breakpoints used for interpretation of results. 
Click on "save and go to next page”  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, enterococcus and staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of methicillin 
resistance. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter the zone diameters in mm and MIC 
values in µg/ml. Remember to use the operator keys to show symbols like “equal to”, etc... If you 
do not use CLSI guidelines for AST of the reference strains, please add a comment on the method 
used. 
Click on "save and go to next page" 
This page is a menu that allows you to review the input pages and approve your input. 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
corrections. If you save a page without changes, you will see an error screen. In this case, click on 
"back" to get back to the page and "go to next page" to continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE! The approval blocks your data entry in the interactive 
database.  
4.2. EQAS on identification and typing of MRSA 
 
Click on “MRSA tests” to start entering your data regarding the MRSA EQAS. 
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Please read carefully the instructions on the webpage and start by answering to the questionnaire on 
the work performed in your laboratory relative to MRSA by clicking on “General MRSA 
questionnaire”.  
Please choose the options that more correctly describe your work on MRSA and before you leave 
this page, click on “Save page” which will take you back to the previous menu. Then, fill in the 
methods used in a second page by clicking on “Methods for MRSA test samples.” 
In the next page you navigate to fields with the Tab-key and mouse.  
Fill in what kind of method you have used for the confirmation of MRSA in this EQAS.  
Click on "Save and go to the next page”  
In the data entry pages for each strain, you enter the obtained results for each of the MRSA EQAS 
strains (EURL ST 7.1...7.10). 
If you wish to participate in the spa typing trial, you will have the option to include the spa-typing 
results. 
If you have performed the spa typing, choose the spa type from the list. If you did not perform spa 
typing, leave the field blank. In case the isolate is not a methicillin resistant Staphylococcus aureus, 
choose “not applicable (N/A)”. Click on "save and go to next page" to navigate to the next sample 
results, until you finish uploading all your data. 
From the last result sheet you get into the general menu, from where you can review the input 
pages: Browse through the pages and make corrections if necessary. Remember to save a page if 
you make any corrections. If you save a page without changes, you will see an error screen, and you 
just have to click on "back" to get back to the page and "go to next page" to continue. 
At the end, approve your input. Be sure that you have filled in all the results before approval, as 
YOU CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive 
database, but allows you to see and print the submitted results. 
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Appendix 5- Examples of TEST FORMS - identification 
and typing of MRSA 
 
Name:       
 
Name of laboratory:       
Name of institute:       
City:       
Country:       
E-mail:       
Fax:       
How many samples did you process in 2012 for MRSA detection? (Choose only one option) 
 less than 50 
 50-100 
 101- 200 
 201-400 
 more than 400 
 
Which kind of samples did you process in your laboratory for MRSA detection in 2012?  
 dust swabs 
  nasal swabs 
  skin swabs 
  faecal samples 
 Boot swabs 
  other matrices  Specify:       
 
Which was the origin of the samples processed for MRSA detection in 2012?  
  from humans 
  environmental 
 from animals  if  you check this answer, please answer the next question 
 other .  Specify:       
 
The samples processed from animals included samples obtained from which species: 
  pigs 
  cattle 
 poultry 
 pets 
 other .  Specify:       
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Any other Comments:       
 
 
TEST FORM – MRSA methods                                                           
 
Method used for confirmatory testing of MRSA (choose only one option) 
 
 PCR using the new EURL recommended multiplex PCR protocol (spa, mecA, 
mecC,and pvl) 
 PCR using the old EURL multiplex PCR protocol (16S rDNA, mecA and nuc) 
  modified protocol but same multiplex PCR primers 
  other published PCR method 
  in- house PCR method 
Describe if you did not use the new EURL recommended method and justify your 
choice:                            
  
Method used for confirmation of species identification (choose only one option) 
 
 PCR using the new EURL recommended multiplex PCR protocol (spa, mecA, 
mecC,and pvl) 
 PCR using the old EURL multiplex PCR protocol (16S rDNA, mecA and nuc) 
  biochemical methods 
  other published PCR method 
  in-house PCR method 
 
Describe if you did not use the EURL recommended method and justify your choice:                
Page 3 of 3 
 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2013 
 
 
 
M00-06-001/21.06.2013 
 
TEST FORM                                                            
Entry data Sample EURL-ST 7.1 
 
Date the testing was started:       
 
Results of confirmatory PCR and species identification: (choose only one option) 
 no isolates tested, sample negative 
 mecA positive, but coagulase-negative Staphylococci (MRCNS) 
 mecA positive, but S . pseudintermedius (MRSP) 
 mecA and mecC negative and not S . aureus (CNS) 
 mecA and mecC negative, S. aureus (MSSA) 
 mecA positive, S. aureus (MRSA)  
 mecC positive, S. aureus (MRSA)  
 
Spa Typing (optional): spa type (choose only one option) 
 Not performed 
 Not applicable (N/A) 
 t011 
 t021 
 t034 
 t075 
 t108 
 t127 
 t337 
 t524 
 t571 
 t843 
 t899 
 t1250 
 t1333 
 t1430 
 t1730 
 t1793 
 t2510 
 t2582 
 t2922 
 t3855 
 t4571 
 t4795 
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